A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

• Status: Completed
• Trial end date: 2017-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Autifony Therapeutics Limited
• Collaborator: University of Manchester
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Male aged 18 to 45 years, inclusive at Visit 1.

• Healthy on the basis of medical history, psychiatric history, physical examination, vital signs, 12-lead electrocardiogram (ECG), haematology, blood chemistry and urinalysis within 6 weeks of Visit 2.

• Right-handed.

• Not a regular smoker (maximum 5 cigarettes per week or equivalent).

Exclusion Criteria:

• History of, or current condition of, migraine headaches or has undergone operations to the head.

• History of significant claustrophobia.